<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047862</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-900-105</org_study_id>
    <nct_id>NCT04047862</nct_id>
  </id_info>
  <brief_title>Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors</brief_title>
  <official_title>Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are : to assess the safety and tolerability, to&#xD;
      determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to&#xD;
      determine the recommended Phase 2 dose (RP2D) of BGB-A1217 (known as Ociperlimab) in&#xD;
      combination with tislelizumab in participants with advanced solid tumors in phase 1.&#xD;
&#xD;
      Primary objective of Phase 1b is to assess overall response rate (ORR) determined by&#xD;
      Investigator per RECIST v1.1 for patients in each dose- expansion&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 Dose Escalation - Number of participants experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v.5.0)</measure>
    <time_frame>Up to 28 Days in Cycle 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 Dose Escalation - Number of participants experiencing Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 1.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1 Dose Escalation - Recommended Phase Ib dose (RP2D) of BGB-A1217 in combination with tislelizumab</measure>
    <time_frame>Up to 1.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b Dose Confirmation - Anti-tumor activity of BGB-1217 in combination with tislelizumab in patients with select advanced solid tumors, in terms of objective response rate (ORR) as assessed by the Investigators using RECIST v. 1.1.</measure>
    <time_frame>Up to 1.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Duration of response (DOR) will be determined from investigator derived tumor assessments per RECIST v. 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Disease control rate (DCR) will be determined from investigator derived tumor assessments per RECIST v. 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Progression free survival will be determined from investigator derived tumor assessments per RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity as assessed by the presence of anti-drug antibodies</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">444</enrollment>
  <condition>Locally Advanced and Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycle 1 (28 Days): A flat dose of BGB-A1217 as a single agent on Day 1. In the first cycle, 200 mg tislelizumab will be administered on Day 8.&#xD;
If BGB-A1217 is tolerated in Cycle 1, participants will receive tislelizumab + BGB-A1217 sequentially on Day 29 and every 21 days for up to 8 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with metastatic squamous NSCLC will receive BGB-A1217 + tislelizumab + paclitaxel/nab-paclitaxel + Carbo once every 3 weeks (Q3W) for 4 to 6 cycles (21 days each) followed by BGB-A1217+tislelizumab Q3W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with metastatic squamous NSCLC will receive BGB-A1217 + tislelizumab + pemetrexed + Cis/Carbo Q3W for 4 to 6 cycles (21 days each) followed by BGB-A1217+tislelizumab Q3W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with metastatic NSCLC (PD-L1 positive, [TPS] ≥ 1%) will be treated with BGB-A1217 + tislelizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with extensive stage SCLC will be treated with BGB-A1217 + tislelizumab + etoposide + Cis/Carbo Q3W for up to 6 to 8 cycles followed by BGB-A1217+tislelizumab Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Checkpoint inhibitor (CPI)-experienced NSCLC patients will be treated with BGB-A1217 plus tislelizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase1b Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with metastatic ESCC will be treated with BGB-A1217 + tislelizumab + cisplatin + 5-fluorouracil /paclitaxel Q3W for 6 cycles followed by BGB-A1217+tislelizumab Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase1b Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with metastatic EAC will be treated with BGB-A1217 + tislelizumab + cisplatin + 5-fluorouracil or paclitaxel Q3W for 6 cycles followed by BGB-A1217+tislelizumab Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase1b Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with recurrent or metastatic HNSCC (PD-L1 positive, vCPS≥ 1%) will be treated with BGB-A1217 + tislelizumab Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase1b Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with metastatic G/GEJ carcinoma will be treated with BGB-A1217 + tislelizumab + [oxalipatin + capecitabine] or [cisplatin + 5-fluorouracil] Q3W for 6 cycles followed by BGB-A1217+tislelizumab + capecitabine Q3W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-A1217</intervention_name>
    <description>Administered as an intravenous (IV) injection</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 1b Cohort 1</arm_group_label>
    <arm_group_label>Phase 1b Cohort 2</arm_group_label>
    <arm_group_label>Phase 1b Cohort 3</arm_group_label>
    <arm_group_label>Phase 1b Cohort 4</arm_group_label>
    <arm_group_label>Phase 1b Cohort 5</arm_group_label>
    <arm_group_label>Phase1b Cohort 6</arm_group_label>
    <arm_group_label>Phase1b Cohort 7</arm_group_label>
    <arm_group_label>Phase1b Cohort 8</arm_group_label>
    <arm_group_label>Phase1b Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Administered as an IV injection</description>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 1b Cohort 1</arm_group_label>
    <arm_group_label>Phase 1b Cohort 2</arm_group_label>
    <arm_group_label>Phase 1b Cohort 3</arm_group_label>
    <arm_group_label>Phase 1b Cohort 4</arm_group_label>
    <arm_group_label>Phase 1b Cohort 5</arm_group_label>
    <arm_group_label>Phase1b Cohort 6</arm_group_label>
    <arm_group_label>Phase1b Cohort 7</arm_group_label>
    <arm_group_label>Phase1b Cohort 8</arm_group_label>
    <arm_group_label>Phase1b Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Administered in accordance with local guidelines, prescribing information/summary of product</description>
    <arm_group_label>Phase 1b Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered in accordance with local guidelines , prescribing information/summary of product</description>
    <arm_group_label>Phase 1b Cohort 1</arm_group_label>
    <arm_group_label>Phase1b Cohort 6</arm_group_label>
    <arm_group_label>Phase1b Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab paclitaxel</intervention_name>
    <description>Administered in accordance with local guidelines , prescribing information/summary of product</description>
    <arm_group_label>Phase 1b Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Administered in accordance with local guidelines , prescribing information/summary of product</description>
    <arm_group_label>Phase 1b Cohort 1</arm_group_label>
    <arm_group_label>Phase 1b Cohort 2</arm_group_label>
    <arm_group_label>Phase 1b Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administered in accordance with local guidelines , prescribing information/summary of product</description>
    <arm_group_label>Phase 1b Cohort 2</arm_group_label>
    <arm_group_label>Phase 1b Cohort 4</arm_group_label>
    <arm_group_label>Phase1b Cohort 6</arm_group_label>
    <arm_group_label>Phase1b Cohort 7</arm_group_label>
    <arm_group_label>Phase1b Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Administered in accordance with local guidelines , prescribing information/summary of product</description>
    <arm_group_label>Phase 1b Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5fluorouracil</intervention_name>
    <description>Administered in accordance with local guidelines , prescribing information/summary of product</description>
    <arm_group_label>Phase1b Cohort 6</arm_group_label>
    <arm_group_label>Phase1b Cohort 7</arm_group_label>
    <arm_group_label>Phase1b Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Administered in accordance with local guidelines , prescribing information/summary of product</description>
    <arm_group_label>Phase1b Cohort 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Administered in accordance with local guidelines , prescribing information/summary of product</description>
    <arm_group_label>Phase1b Cohort 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        Phase 1 Key Inclusion Criteria&#xD;
&#xD;
          1. Has Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1.&#xD;
&#xD;
          2. ≥ 1 measurable lesion per RECIST v1.1.&#xD;
&#xD;
          3. Has adequate organ function.&#xD;
&#xD;
          4. phase 1- Patients with histologically or cytologically confirmed advanced, metastatic,&#xD;
             unresectable solid tumors who have previously received standard systemic therapy or&#xD;
             for which treatment is not available, not tolerated or refused.&#xD;
&#xD;
        Phase 1b Key Inclusion Criteria&#xD;
&#xD;
          1. Signed informed consent form (ICF) and able to comply with study requirements.&#xD;
&#xD;
          2. Age ≥ 18 years (or the legal age of consent) at the time the ICF is signed.&#xD;
&#xD;
          3. Histologically or cytologically confirmed tumor types in the following disease&#xD;
             cohorts:&#xD;
&#xD;
             Cohort 1: stage IV squamous NSCLC Cohort 2: stage IV non-squamous NSCLC Cohort 3:&#xD;
             stage IV squamous or non-squamous NSCLC with PD-L1 positive. Cohort 4: extensive-stage&#xD;
             SCLC Cohort 5: stage IIIB, IIIC or IV NSCLC Cohort 6: stage IV ESCC Cohort 7: stage IV&#xD;
             EAC Cohort 8: recurrent or metastatic HNSCC incurable by local therapies Cohort 9:&#xD;
             stage IV G/GEJ adenocarcinoma.&#xD;
&#xD;
          4. ECOG Performance Status ≤ 1&#xD;
&#xD;
          5. Adequate organ function&#xD;
&#xD;
          6. Willing to use highly effective method of birth control&#xD;
&#xD;
        Phase 1 Key Exclusion Criteria:&#xD;
&#xD;
          1. Active brain or leptomeningeal metastasis.&#xD;
&#xD;
          2. Active autoimmune diseases or history of autoimmune diseases that may relapse.&#xD;
&#xD;
          3. With severe chronic or active infections requiring systemic antibacterial, antifungal&#xD;
             or antiviral therapy, including tuberculosis infection, etc. (antiviral therapy is&#xD;
             permitted for patients with hepatocellular carcinoma).&#xD;
&#xD;
          4. Concurrent participation in another therapeutic clinical trial.&#xD;
&#xD;
          5. Received prior therapies targeting TIGIT.&#xD;
&#xD;
        Phase 1b Key Exclusion Criteria:&#xD;
&#xD;
          1. Patients with any prior therapy for recurrent/metastatic disease.&#xD;
&#xD;
          2. Non-squamous NSCLC patients with sensitizing epidermal growth factor receptor (EGFR)&#xD;
             mutation, anaplastic lymphoma kinase (ALK) fusion, and c-ros oncogene 1 (ROS1) fusion.&#xD;
&#xD;
          3. Gastric cancer patients with squamous or with positive HER2 expression.&#xD;
&#xD;
          4. Prior therapy with any drug specifically targeting T-cell co-stimulation or checkpoint&#xD;
             pathways. (anti-PD(L)1 exception for Cohort 5).&#xD;
&#xD;
          5. Active leptomeningeal disease or uncontrolled brain metastasis.&#xD;
&#xD;
          6. Active autoimmune diseases or history of autoimmune diseases that may relapse.&#xD;
&#xD;
          7. With severe chronic or active infections requiring systemic antibacterial, antifungal&#xD;
             or antiviral therapy, including tuberculosis infection, etc. (antiviral therapy is&#xD;
             permitted for patients with hepatocellular carcinoma).&#xD;
&#xD;
          8. Concurrent participation in another therapeutic clinical study.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarek Meniawy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linear Clinical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1-877-828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moores Comprehensive Cancer Center/UC San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rutgers-Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Center for Cancer Care</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Portland</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Pavillion</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute(SCRI)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2146</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Foundation</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metro South Health, Cancer Trials Unit Division of Cancer Services - PAH</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Adelaide Cancer Centre (Ashford Cancer Centre (ACC)) - 480 Specialist Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5087</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Hobart Hospital (RHH)</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Hospital</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St John of God - Subiaco Hospital - Bendat Family Comprehensive Cancer Centre (BFCCC)</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jilin Cancer Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>132000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center (NCC)</name>
      <address>
        <city>Goyang-si</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gachon University School of Medicine - Gachon University Gil Hospital (Gil Medical Center)</name>
      <address>
        <city>Seongnam-si</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea - Seoul St. Mary's Hospital (Kangnam St. Mary's Hospital)</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea - St. Vincent's Hospital - Lung Cancer Center</name>
      <address>
        <city>Seoul</city>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christchurch Clinical Studies</name>
      <address>
        <city>Christchurch</city>
        <zip>8140</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital</name>
      <address>
        <city>Guishan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Buddhist Tzu Chi General Hospital - Hualien Tzu Chi Medical Center</name>
      <address>
        <city>Hualien City</city>
        <zip>970</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chi-Mei Hospital, Liouying</name>
      <address>
        <city>Yongkang</city>
        <zip>73657</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital (NTUH)</name>
      <address>
        <city>Zhongzheng</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BGB-A1217</keyword>
  <keyword>Anti-TIGIT antibody</keyword>
  <keyword>Tislelizumab</keyword>
  <keyword>anti-PD-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

